Cyclopharm Limited

CYC

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. The firm's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The firm uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The firm distributes its products in approximately 65 countries.

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

BHP Group Limited

BHP

BHP Group Ltd. engages in the exploration, development, production and processing of iron ore, metallurgical coal, and copper. The company is headquartered in Melbourne, Victoria and currently employs 39,729 full-time employees. The firm is a producer of commodities, including iron ore, copper, nickel, potash and metallurgical (steelmaking) coal. The company is focused on offering a range of resources, which provides copper for renewable energy; nickel for electric vehicles; potash for sustainable farming, and iron ore and metallurgical coal for the steel needed for global infrastructure and the energy transition. Its segments include Copper, Iron Ore, and Coal. Its Copper segment is engaged in mining of copper, silver, zinc, molybdenum, uranium, and gold. Its Iron Ore segment is engaged in mining of iron ore. Its Coal segment is engaged in mining of metallurgical coal and energy coal. The firm is also focused on operating Olympic Dam, Prominent Hill, and Carrapateena underground copper-gold mines in South Australia. Its operations are situated in Australia, Europe, China, Japan, India, South Korea, rest of Asia, North America, South America, and others.

Big River Industries Limited

BRI

Big River Industries Ltd. operates through Big River Group Pty Ltd, which engages in the manufacture and distribution of timber and building products. The Company’s principal activities include the manufacture of veneer, plywood and formply, and the distribution of building supplies. Its segments include Panels and Construction. The Panels segment comprises three manufacturing and six distribution sites of timber panel products in Australia and New Zealand. The Construction segment is comprised of 17 sites which sell building, commercial and formwork products in Australia. The company is an integrated Australian timber products business that operates across the full continuum from procurement of raw materials through to sale of finished products to end users. The company is a manufacturer of softwood and hardwood formply and structural plywood products in Australia. The company also sells consumable formwork products in Australia. The company is a national merchant of timber and associated building products to local trade, medium-sized and enterprise-sized companies.

Infomedia Ltd

IFM

Infomedia Ltd. engages in the development and provision of applications and information solutions in the after sales parts and service sector of the automotive industry. The company is headquartered in Belrose, New South Wales. The company went IPO on 2000-08-16. Its segments include Asia Pacific; Europe, Middle East and Africa (EMEA), and Americas, representing the combined North, Central and South America. Its parts include Microcat EPC, Microcat Partsbridge, Microcat Market, Microcat CRM, Microcat Messenger and Microcat EPC Origins. Its SaaS service selling platform includes Superservice Menus, Superservice Triage, Superservice Register and Superservice Connect. Its DaaS and insights platform, Infodrive, combines data analytics with its expertise in global aftersales to drive predictive marketing and dealer performance programs for global automakers. Its SimplePart is a provider business to business and business to consumer aftersales e-commerce solutions. SimplePart’s intuitive platform provides automakers and dealers with a branded Website, online store and digital marketing support to improve sales.